CIS

Home page

CIS

Russia, Italy working on treatment of COVID-19 with plasma-based drugs

14 May 2020 17:46 (UTC +04:00)

The Russian Direct Investment Fund (RDIF) is working together with Kedrion, an Italian company, and with the FSI investment fund on launching a project on treating COVID-19, a disease caused by the novel coronavirus, using drugs based on human blood plasma, the fund’s press release informs, APA reports citing TASS.

"The RDIF is actively cooperating with Italian companies in the sphere of medical technology to find new means of combating the coronavirus. Together with one of the global leaders in the production of blood plasma-based products, the Kedrion company, and the FSI investment fund, we are working on launching a project in Russia on treating the coronavirus with drugs based on human blood plasma," head of the fund Kirill Dmitriev said.

Besides, the RDIF is cooperating with Italy in other areas in order to fight the coronavirus. Russian military medics sent to Italy used the EMG mobile test systems produced with the support of the fund.

The press service also noted that Dmitriev has been honored with the Star of Italy medal, a state award for significant contribution to the development of bilateral investment cooperation. The official award ceremony will take place in the Italian Embassy in Moscow when the coronavirus-related restrictions are lifted.